Savara (NASDAQ:SVRA) Stock Price Down 5.1% – What’s Next?

Savara Inc. (NASDAQ:SVRA) shares were down 5.1% during mid-day trading on Tuesday . The company traded as low as $6.05 and last traded at $6.0070. Approximately 901,501 shares were traded during mid-day trading, a decline of 43% from the average daily volume of 1,587,894 shares. The stock had previously closed at $6.33.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on SVRA shares. Citigroup reaffirmed an “outperform” rating on shares of Savara in a report on Thursday, October 23rd. UBS Group set a $10.00 target price on Savara in a research report on Tuesday, December 23rd. HC Wainwright lifted their price target on Savara from $8.00 to $10.00 and gave the stock a “buy” rating in a research report on Tuesday, December 23rd. Wall Street Zen upgraded Savara from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Finally, Wells Fargo & Company increased their price objective on Savara from $7.00 to $9.00 and gave the company an “overweight” rating in a report on Thursday, December 18th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $9.13.

Savara Stock Down 5.2%

The company has a current ratio of 7.65, a quick ratio of 7.65 and a debt-to-equity ratio of 0.32. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of -11.33 and a beta of 0.22. The firm’s 50 day moving average is $5.27 and its two-hundred day moving average is $3.76.

Savara (NASDAQ:SVRA) last released its earnings results on Wednesday, November 12th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01). On average, sell-side analysts predict that Savara Inc. will post -0.45 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Sivia Capital Partners LLC raised its position in shares of Savara by 9.1% in the 2nd quarter. Sivia Capital Partners LLC now owns 41,500 shares of the company’s stock worth $95,000 after buying an additional 3,459 shares during the period. BNP Paribas Financial Markets boosted its position in Savara by 52.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock valued at $31,000 after buying an additional 4,626 shares during the last quarter. Farther Finance Advisors LLC grew its stake in Savara by 17.6% during the 2nd quarter. Farther Finance Advisors LLC now owns 38,001 shares of the company’s stock valued at $87,000 after purchasing an additional 5,687 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Savara by 14.2% in the second quarter. The Manufacturers Life Insurance Company now owns 51,930 shares of the company’s stock worth $118,000 after buying an additional 6,449 shares during the last quarter. Finally, Sio Capital Management LLC increased its position in shares of Savara by 1.0% in the 2nd quarter. Sio Capital Management LLC now owns 726,851 shares of the company’s stock worth $1,657,000 after purchasing an additional 7,197 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.